LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) — The Schall Regulation Agency, a nationwide shareholder rights litigation agency, reminds buyers of a category motion lawsuit towards ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Change Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Change Fee.
Buyers who bought the Firm’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”), are inspired to contact the agency earlier than Might 26, 2026.
If you’re a shareholder who suffered a loss, click on right here to take part.
The category, on this case, has not but been licensed, and till certification happens, you aren’t represented by an legal professional. For those who select to take no motion, you may stay an absent class member.
In accordance with the Grievance, the Firm made false and deceptive statements to the market. ImmunityBio overstated the capabilities of its Anktiva drug. Based mostly on these information, the Firm’s public statements have been false and materially deceptive all through the category interval. When the market realized the reality about ImmunityBio, buyers suffered damages.
More Read
Be a part of the case to recuperate your losses
The Schall Regulation Agency represents buyers all over the world and makes a speciality of securities class motion lawsuits and shareholder rights litigation.
This press launch could also be thought of Legal professional Promoting in some jurisdictions underneath the relevant regulation and guidelines of ethics.
More Read
CONTACT:
SOURCE:
The Schall Regulation Agency
